DK2958558T3 - Fremgangsmåder og sammensætninger til behandling af leukæmi - Google Patents

Fremgangsmåder og sammensætninger til behandling af leukæmi Download PDF

Info

Publication number
DK2958558T3
DK2958558T3 DK14754927.3T DK14754927T DK2958558T3 DK 2958558 T3 DK2958558 T3 DK 2958558T3 DK 14754927 T DK14754927 T DK 14754927T DK 2958558 T3 DK2958558 T3 DK 2958558T3
Authority
DK
Denmark
Prior art keywords
leukemia
compound
composition
use according
alkyl
Prior art date
Application number
DK14754927.3T
Other languages
English (en)
Inventor
Sheng-Yung Liu
Wu-Che Wen
Chih-Ming Chen
Original Assignee
Golden Biotechnology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Golden Biotechnology Corp filed Critical Golden Biotechnology Corp
Application granted granted Critical
Publication of DK2958558T3 publication Critical patent/DK2958558T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
    • C07C50/28—Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (15)

1. Farmaceutisk sammensætning, der omfatter en terapeutisk effektiv mængde af en cyclohexenonforbindelse med strukturen:
hvor hver af X og Y uafhængigt er oxygen, NRs eller svovl; R er en hydrogen eller C(=0)Ci-C8alkyl; hver af Ri, R2 og R3 uafhængigt er hydrogen, eventuelt substitueret methyl eller (CH2)m-CH3; R4 er NRsRe, OR5, 0C(=0)R7, C(=0)0Rs, C(=0)Rs, C(=0)NRsR6, halogen, en 5 eller 6-leddet lacton, Ci-Csalkyl, C2-Csalkenyl, C2-Csalkynyl, aryl, glucosyl, hvor den 5 eller 6-leddede lacton, Ci-Cealkyl, C2-Cealkenyl, C2-Cealkynyl, aryl og glucosyl eventuelt er substitueret med en eller flere substituenter valgt blandt NRsRe, ORs, 0C(=0)R7, C( = 0)0Rs, C(=0)Rs, C(=0)NR5Re, Ci-Csalkyl, C2-Csalkenyl, C2-Csalkynyl, Cs-Cecycloalkyl og Ci-Cehalogenalkyl; hver af Rs og R6 uafhængigt er hydrogen eller Ci-Cealkyl; R7 er Ci-Csalkyl, ORs eller NRsRe; m = 1-12; og n = l-12; eller et farmaceutisk acceptabelt salt eller solvat deraf; til anvendelse til behandling af eller reducering af risikoen for leukæmi hos et individ.
2. Sammensætning til anvendelse ifølge krav 1, hvor leukæmien er en akut leukæmi.
3. Sammensætning til anvendelse ifølge krav 1, hvor leukæmien er kronisk leukæmi.
4. Sammensætning til anvendelse ifølge krav 2, hvor den akutte leukæmi er en akut myeloid leukæmi, akut erythroid leukæmi, akut lymfoblastisk leukæmi, akut lymfoblastisk T-celle-leukæmi, T-celle-leukæmi/lymfom hos voksne, forstadie T akut lymfoblastisk leukæmi/lymfom eller blastkrise ved kronisk myeloid leukæmi.
5. Sammensætning til anvendelse ifølge krav 3, hvor den kroniske leukæmi er en kronisk myeloid leukæmi, kronisk lymfocytisk leukæmi, hårcelleleukæmi.
6. Sammensætning til anvendelse ifølge krav 5, hvor den kroniske leukæmi er en kronisk myeloid leukæmi.
7. Sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvor cyclohexenonforbindelsen eller et farmaceutisk acceptabelt salt eller solvat deraf anvendes oralt, parenteralt, intravenøst eller ved injektion.
8. Sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvor individet er et menneske.
9. Sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvor R er hydrogen, C(=0)C3H8, C(=0)C2H5 eller C(=0)CH3.
10. Sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvor hver af Ri, R2 og R3 uafhængigt er hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl eller octyl.
11. Sammensætning til anvendelse ifølge krav 10, hvor hver af Ri og R2 uafhængigt er hydrogen eller methyl.
12. Sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvor R4 er C2H5C(CH3)20H, C2H5C(CH3)20CH3, CH2COOH, C2H5COOH, CH2OH, C2H5OH, CH2Ph, C2H5Ph, CH2CH=C(CH3)(CHO), CH2CH=C(CH3)(C(=0)CH3), en 5 eller 6-leddet lacton, aryl eller glucosyl, hvor den 5 eller 6-leddede lacton, aryl og glucosyl eventuelt er substitueret med en eller flere substituenter valgt blandt NR5R6, OR5, 0C(=0)R7, C(=0)0Rs, C(=0)Rs, C(=0)NR5Re, Ci-Cealkyl, C2-C8alkenyl, C2-Cealkynyl, Cs-Cecycloalkyl og Ci-Cehalogenalkyl.
13. Sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvor R4 er Ci-Csalkyl, der eventuelt er substitueret med en eller flere substituenter valgt blandt NR5R6, OR5, 0C(=0)R7, C(=0)0R5, C(=0)Rs, C(=0)NR5Re, Ci-Csalkyl, C2-Csalkenyl, C2-Cealkynyl, C3-Cecycloalkyl og Ci-Cehalogenalkyl.
14. Sammensætning til anvendelse ifølge krav 13, hvor R4 er CH2CH=C(CH3)2.
15. Sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvor forbindelsen er
DK14754927.3T 2013-02-20 2014-02-20 Fremgangsmåder og sammensætninger til behandling af leukæmi DK2958558T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361767211P 2013-02-20 2013-02-20
PCT/US2014/017285 WO2014130619A2 (en) 2013-02-20 2014-02-20 Methods and compositions for treating leukemia

Publications (1)

Publication Number Publication Date
DK2958558T3 true DK2958558T3 (da) 2018-09-24

Family

ID=51391965

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14754927.3T DK2958558T3 (da) 2013-02-20 2014-02-20 Fremgangsmåder og sammensætninger til behandling af leukæmi

Country Status (16)

Country Link
US (1) US9403747B2 (da)
EP (1) EP2958558B1 (da)
JP (1) JP6501123B2 (da)
KR (1) KR102054038B1 (da)
CN (2) CN108309961A (da)
AU (1) AU2014218938B2 (da)
BR (1) BR112015019924A2 (da)
CA (1) CA2901745A1 (da)
DK (1) DK2958558T3 (da)
ES (1) ES2687286T3 (da)
HK (2) HK1219884A1 (da)
MX (1) MX2015010728A (da)
PL (1) PL2958558T3 (da)
TW (1) TWI597061B (da)
WO (1) WO2014130619A2 (da)
ZA (1) ZA201506330B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3416630B1 (en) * 2016-02-17 2023-10-25 Golden Biotechnology Corporation Compositions and methods for treating liver cancer
MY194948A (en) * 2016-05-13 2022-12-28 Golden Biotechnology Corp Methods and compositions for treating advanced stage non-small cell lung cancer
TWI601535B (zh) * 2016-06-23 2017-10-11 台灣利得生物科技股份有限公司 牛樟段木栽培牛樟芝子實體及固態培養菌絲體水及乙醇萃取物之組合物應用於抗癌藥輔助劑
CN107540641A (zh) * 2016-06-29 2018-01-05 彭朗 一种新的有机酯类化合物及其制备方法和医药用途
US10314241B1 (en) * 2016-09-14 2019-06-11 T. Scott Dunn Airborne vegetation cutting assembly
US11406605B2 (en) * 2017-12-20 2022-08-09 Golden Biotechnology Corporation Therapeutic compositions for treating pancreatic cancer
US11253527B2 (en) * 2019-02-25 2022-02-22 Arjil Biotech Holding Company Limited Method and composition for inhibiting virus infection
US11548069B2 (en) 2019-05-20 2023-01-10 Wisconsin Alumni Research Foundation Three-dimensional printer laminating fusible sheets
CN121673157A (zh) * 2026-02-09 2026-03-17 赣州市人民医院 一种蒽醌化合物及其提取方法和应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US5905089A (en) * 1997-04-14 1999-05-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Use of sesquiterpene lactones for treatment of severe inflammatory disorders
US5869090A (en) 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
US20070287672A1 (en) * 2004-04-20 2007-12-13 Donald Creighton Macromolecular Gsh-Activiated Glyoxylase I Inhibitors
US20080081053A1 (en) * 2004-09-30 2008-04-03 Bedrosian Camille L Treatment Method
CN101343247B (zh) * 2007-07-12 2011-01-19 国鼎生物科技股份有限公司 牛樟芝的环己烯酮萃取物
TW200918498A (en) * 2007-10-19 2009-05-01 Golden Biotechnology Corp Novel compound isolated from Antrodia camphorate extracts
TWI389699B (zh) * 2009-02-13 2013-03-21 高雄醫學大學 用於誘導細胞凋亡之樟芝子實體乙醇萃取物及其製備方法
TW201102075A (en) * 2009-07-09 2011-01-16 Golden Biotechnology Corp Cyclohexenone compound of Antrodia cinnomomea that suppresses growth of tumor cell of pancreatic cancer
TW201109013A (en) * 2009-09-09 2011-03-16 Golden Biotechnology Corp Cyclohexenone chemical compounds of Antrodia cinnamomea for suppressing the growth of the Lymphoma tumor cell
ES2574606T3 (es) * 2009-11-26 2016-06-21 National Taiwan University Una sustancia activa contra el cáncer de Antrodia camphorata, método de preparación de la misma y uso de la misma
CN102232942B (zh) * 2010-05-06 2013-03-27 国鼎生物科技股份有限公司 用于抑制淋巴癌肿瘤细胞生长的牛樟芝环己烯酮化合物
US8309611B2 (en) * 2010-09-20 2012-11-13 Golden Biotechnology Corporation Methods and compositions for treating lung cancer
JP2013544827A (ja) * 2010-11-24 2013-12-19 エクセリクシス， インク． ＰＩ３Ｋ／ｍＴＯＲの阻害剤としてのベンゾオキサゼピン類ならびにそれらの使用法および製造法
TWI444189B (zh) * 2011-05-31 2014-07-11 Mackay Memorial Hospital 羊毛甾醇－８，２４－二烯－３β，１５α，２１－三醇抑制腫瘤細胞生長之用途
AU2012267893A1 (en) * 2011-06-10 2013-12-19 Golden Biotechnology Corporation Methods and compositions for treating brain cancer
TWI484954B (zh) * 2011-10-11 2015-05-21 New Bellus Entpr Co Ltd 用於治療癌症之醫藥組合物
US20150018296A1 (en) * 2013-03-15 2015-01-15 Golden Biotechnology Corporation Therapeutic methods and compositions utilizing cyclohexenone compounds

Also Published As

Publication number Publication date
EP2958558A2 (en) 2015-12-30
US20150025135A1 (en) 2015-01-22
TW201446240A (zh) 2014-12-16
ZA201506330B (en) 2016-10-26
AU2014218938A1 (en) 2015-09-10
EP2958558B1 (en) 2018-06-13
BR112015019924A2 (pt) 2017-07-18
EP2958558A4 (en) 2016-08-10
CN108309961A (zh) 2018-07-24
KR102054038B1 (ko) 2019-12-09
JP2016509058A (ja) 2016-03-24
WO2014130619A3 (en) 2014-10-16
AU2014218938B2 (en) 2018-12-06
ES2687286T3 (es) 2018-10-24
WO2014130619A2 (en) 2014-08-28
TWI597061B (zh) 2017-09-01
MX2015010728A (es) 2016-04-11
CA2901745A1 (en) 2014-08-28
HK1255453A1 (zh) 2019-08-16
PL2958558T3 (pl) 2018-12-31
JP6501123B2 (ja) 2019-04-17
US9403747B2 (en) 2016-08-02
CN105246470A (zh) 2016-01-13
KR20150120424A (ko) 2015-10-27
HK1219884A1 (zh) 2017-04-21

Similar Documents

Publication Publication Date Title
DK2958558T3 (da) Fremgangsmåder og sammensætninger til behandling af leukæmi
CA2809762C (en) Methods and compositions for treating lung cancer
AU2013348248B2 (en) Methods and compositions for treating neurodegenerative diseases
US20150018296A1 (en) Therapeutic methods and compositions utilizing cyclohexenone compounds
US20130158113A1 (en) Methods and compositions for treating brain cancer
US10905656B2 (en) Methods and compositions for treating arteriosclerotic vascular diseases
US20130203861A1 (en) Methods and compositions for treating ovarian cancer
AU2017363153B2 (en) Methods and compositions for treating atopic dermatitis
US20130142882A1 (en) Methods and compositions for treatment, modification and management of bone cancer pain
CA3043036C (en) Methods and compositions for treating atopic dermatitis